Kineret Taler Email

Head Preclinical Studies . NurExone Biologic (OTCQBNRXBF) (TSXV NRX) (FSE J90)

Haifa,

Location

k******@nurexone.com

Primary Email

https://www.linkedin.com/in/kineret-taler

How to contact Kineret Taler

Join and see Kineret's contact info for free!

k******@nurexone.com

Current Roles

NurExone Biologic (OTCQBNRXBF) (TSXV NRX) (FSE J90)

Employees:

Revenue:

$5.3M

About

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.\nThe breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

NurExone Biologic (OTCQBNRXBF) (TSXV NRX) (FSE J90) Address

Haifa, null
IL